Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

DraftKings (NASDAQ: DKNG) is forecasting robust growth in revenue and profitability in 2025. Read More: Earn up to $845 cash ...

Buy, sell or hold strategy on LIC, NTPC, PFC, Asian Paints, IGL, over a dozen other stocks today Traders' Diary: Buy, sell or ...

The overall value in Carnival stock is compelling here, making it more a buy than a sell or even a hold. This was an industry ...

Stodgy tobacco stock Altria Group ( MO 0.18%), most known for selling Marlboro cigarettes in the U.S. and paying hefty ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

CAT's Q3 earnings and revenue guidance disappoints, with a weak end-user demand impacting volumes. Shares of the company dip ...

Despite volatility in gold prices, the sustained revenue momentum in Q2 was led by robust footfall post custom duty cut from ...

Entergy has strong growth potential but appears overvalued. See why ETR stock’s favorable regulatory environment and dividend ...

Stock Market Today: Adani Power share price gained more than 7% in morning trades on Wednesday. Adani power recently ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Omnichannel commerce platform provider Shopify (SHOP) delivered solid quarterly numbers. For the third quarter (Q3), the ...